Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Study Details
Study Description
Brief Summary
This phase Ib trial tests the safety, side effects, and best dose of a enasidenib in combination with cobimetinib in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving enasidenib and cobimetinib may kill more cancer cells in patients with relapsed or refractory acute myeloid leukemia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
PRIMARY OBJECTIVES:
-
Assess the safety and tolerability of cobimetinib in combination with enasidenib.
-
Determine the maximum tolerated dose(s) (MTD) and recommended phase 2 dose (RP2D).
SECONDARY OBJECTIVES:
-
Obtain preliminary estimates of clinical activity as measured by the complete remission (complete response [CR], complete response with incomplete hematologic recovery [CRi], or complete response with partial hematologic recovery [CRh]) rate and minimal residual disease (MRD) rate.
-
Obtain preliminary estimates of clinical activity as measured by overall response rate (CR, CRi, CRh, morphologic leukemia free state [MLFS], and partial response [PR]).
-
Obtain preliminary estimates of median time to complete remission. IV. Obtain preliminary estimates of median time to first response. V. Obtain preliminary estimates of response duration in all participants and in those attaining CR/CRi/CRh.
-
Obtain preliminary estimates of median and 1-year event-free survival (EFS).
-
Obtain preliminary estimates of median and 1-year overall survival (OS).
EXPLORATORY OBJECTIVES:
-
Characterize the effects of the combination on cellular differentiation of leukemic cells as measured by flow cytometry performed at study entry and at serial timepoints throughout the study.
-
Evaluate changes in promotor methylation patterns after treatment with combination therapy.
-
Evaluate changes in gene expression of RAS pathway regulators as a result of the combination therapy.
OUTLINE: This is dose-escalation study of cobimetinib followed by a dose-expansion study.
Patients receive cobimetinib orally (PO) once daily (QD) on days 1-21 and enasidenib mesylate PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, and every 3 months for 1 year at last treatment dose.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (cobimetinib, enasidenib mesylate) Patients receive cobimetinib PO QD on days 1-21 and enasidenib mesylate PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. |
Drug: Cobimetinib
Given PO
Other Names:
Drug: Enasidenib Mesylate
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Dose limiting toxicity [Cycle 1 (28 days)]
Toxicity will be graded according to the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
- Incidence of adverse events [Up to 30 days after last dose of study drug]
Toxicity will be graded according to the NCI- CTCAE version 5.0. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment and reversibility or outcome.
Secondary Outcome Measures
- Response [Up to 1 year]
Response will be determined using European LeukemiaNet (ELN) criteria.
- Minimal residual disease (MRD) status [Up to 1 year]
MRD status will be determined by standard of care (SOC) flow cytometry assay.
- Complete remission [Up to 1 year]
Time to complete remission is defined as time from first study dose to attainment of complete response(CR), complete response with incomplete hematologic recovery CRi, or complete response with partial hematologic recovery CRh). Will calculate rates and 95% Clopper-Pearson binomial confidence interval (CI).
- Time to first response [From first study does to first documented complete response, assessed up to 3 years]
Time to first response is defined as time from first study dose to attainment of first documented CR, CRi, CRh, morphologic leukemia free state (MLFS), or partial response (PR). Will calculate rates and 95% Clopper-Pearson binomial CI.
- Response duration [From first study does to first documented complete response, assessed up to 1 year]
Response Duration is defined as the time from the date of first documented response (CR, CRi, CRh, MLFS or PR) to documented disease relapse/progression or death, whichever occurs first. Will be estimated using the product-limit method of Kaplan and Meier.
- Event-free survival (EFS) [From first study dose to first documented complete response to relapse/progression (> 5% blasts, reappearance of blasts in blood, or development of extramedullary disease) or death, whichever occurs first, assessed up to 1 year]
Will be estimated using the product-limit method of Kaplan and Meier.
- Overall survival (OS) [From first study dose to death from any cause, assessed up to 1 year]
Will be estimated using the product-limit method of Kaplan and Meier.
Other Outcome Measures
- Level of myeloid differentiation [Up to 1 year]
Level of myeloid differentiation on pre and post-treatment peripheral blood (PB) and bone marrow (BM) samples by flow cytometry.
- Promotor methylation status of RAS pathway regulator [Up to 1 year]
Promotor methylation status of RAS pathway regulators by enhanced reduced representation bisulfite sequencing.
- Changes in RAS pathway regulatory gene expression levels [Pre and post- treatment, assessed up to 1 year]
Changes in RAS pathway regulatory gene expression levels by ribonucleic acid (RNA) sequencing pre- and post-treatment. Will use Next generation sequencing (HopeSeq) and/or rapid sequencing assays (Rapid AML Panel).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Documented informed consent of the participant and/or legally authorized representative
-
Age: >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
-
Patients with histologically confirmed acute myeloid leukemia (AML), according to World Health Organization (WHO) criteria, with refractory/relapsed (R/R) disease who are ineligible for therapies known to be effective for treatment of their acute myeloid leukemia (AML)
-
Patients with non-central nervous system (CNS) extramedullary disease may be included if they also have marrow involvement
-
Patients with acute promyelocytic leukemia (APL) will not be eligible
-
Patients with IDH2 mutations, who were previously treated with enasidenib are allowed
-
Have a confirmed susceptible IDH2 mutation (R140 or R172) with a concomitant RAS-pathway mutation, involving NRAS, KRAS, PTPN11, CBL or NF1 genes
-
Fully recovered from the acute toxic effects (except alopecia) to =< Grade 1 to prior anti-cancer therapy
-
Ability to swallow pills
-
Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (performed within 14 days prior to day 1 of protocol therapy)
-
Aspartate aminotransferase (AST) =< 2.0 x ULN (performed within 14 days prior to day 1 of protocol therapy)
-
Alanine aminotransferase (ALT) =< 2.0 x ULN (performed within 14 days prior to day 1 of protocol therapy)
-
Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy)
-
International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN
-
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy)
-
Left ventricular ejection fraction (LVEF) >= 50%
-
Note: Echocardiogram scan to be performed within 7 days prior to day 1 of protocol therapy
-
Tricuspid valve regurgitation jet (TRJ) velocity < 2.5 m/sec
-
Note: To be performed within 7days prior to day 1 of protocol therapy
-
Corrected QT (QTc) =< 480 ms
-
Note: To be performed within 28 days prior to day 1 of protocol therapy
-
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Agreement by females and males of childbearing potential* to use an effective method of birth control (non-hormonal) or abstain from heterosexual activity from 4 weeks prior to first dose of study treatment through at least 2 months after the last dose of protocol therapy. Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives
-
Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).
-
Also, male subjects should refrain from sperm donation from the start of treatment throughout the study treatment period and for 6 months following the last dose of treatment
Exclusion Criteria:
-
Current or planned use of other investigational agents, antineoplastic, chemotherapy, radiation therapy, biological therapy, immunotherapy or major surgery within 4 weeks or 5 half-lives, whichever is shorter, prior to Day 1 of protocol therapy (exception: hydroxyurea is allowed in cycles 1 and 2 for control of rapidly progressing leukemia or for treatment of enasidenib-related leukocytosis)
-
Systemic steroid therapy > 10 mg/day (=< 10mg/day prednisone equivalent ok) or any other form of immunosuppressive medication within 28 days, except as required for treatment of differentiation syndrome
-
Strong and moderate CYP3A4 inducers/inhibitors (moderate CYP3A4 inhibitors only allowed on principal Investigator approval) within 14 days prior to Day 1 of protocol therapy
-
Foods/supplements that are strong and moderate inhibitors or inducers of CYP3A (such as grapefruit, Seville oranges, starfruit and St. John's wort) within 7 days prior to initiation of and during study treatment
-
Received a live-virus vaccination within 28 days of planned treatment start
-
Concurrent use of granulocyte-macrophage colony stimulating factor (GMCSF) or granulocyte colony stimulating factor (G-CSF), erythropoietin, eltrombopag, or other hematopoietic growth factors 14 days prior to start of study
-
Class III/IV cardiovascular disability according to the New York Heart Association Classification
-
Participants with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of enrollment. Subjects with controlled, asymptomatic atrial fibrillation can enroll
-
History of acute cardiovascular ischemic event, i.e., myocardial infarction or unstable angina within 6 months of enrollment
-
Participant has ophthalmologic conditions, including any of the following:
-
Current or past history of central serous retinopathy
-
Current or past history of retinal vein occlusion
-
Intraocular pressure (IOP) > 21 mmHg or uncontrolled glaucoma
-
Gastrointestinal disorder such as malabsorption syndrome or any other disorder that may interfere with oral drug absorption
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
-
Active central nervous system (CNS) disease
-
Clinically significant uncontrolled illness
-
Active infection requiring antibiotics
-
Other active malignancy
-
Females only: Pregnant or breastfeeding
-
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
-
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | City of Hope Medical Center | Duarte | California | United States | 91010 |
Sponsors and Collaborators
- City of Hope Medical Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Brian Ball, City of Hope Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 21751
- NCI-2022-04926
- 21751
- P30CA033572